AndreaBozzo/ceres-open-data-index huggingface dataset:
Managed Care Institutional Provider Network Data: September 30, 2017

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of health plans in New York State. Beginning in 2017, the PNDS includes Medicaid Managed Care (MMC), HIV Special Need Plans (SNP), Health and Recovery Plans (HARP), Child Health Plus (CHP), Programs of All-Inclusive Care for the Elderly (PACE), Non-PACE Managed Long-Term Care (MLTC) plans, Qualified Health Plans (QHP), Essential Plans (EP), and commercial plans. This dataset reflects institutional provider data. Provider Network Data System information is self-reported by health plans. The PNDS data dictionary can be found at http://www.health.ny.gov/health_care/managed_care/docs/dictionary.pdf . To use the NYS Provider & Health Plan Look-Up Tool, click on the following link: https://pndslookup.health.ny.gov/ .
The Flint MDT Study (March 2014- January 2016)

The Flint MDT Study is one of the projects of the the National Quality Improvement Center on the Representation of Children in Child Welfare (QIC-ChildRep). The Study partnered with a group of five lawyers-guardian ad litem to observe and evaluate a multidisciplinary approach to representing children in child protection proceedings. The study provided the LGALs two social workers and randomly assigned cases to be either represented by the attorney/social worker team or by the attorney alone.  This study provides both a description of the functioning of these teams collaborating to represent children  and a rigorous evaluation of outcomes compared to a control group.  Only quantitative data have been deposited with NDACAN.

Investigators: Pott, R.
Compound 528608: Butanamide, N-isopropyl-3-methyl

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-N-propan-2-ylbutanamide. Molecular Formula: C8H17NO. Molecular Weight: 143.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms. In this review, we present a systematic overview of these trials.
Inhaled nitric oxide in persistent pulmonary hypertension of the
		  newborn refractory to high-frequency ventilation

Background:
          This study was designed to evaluate the effect of nitric oxide
				(NO) on the management of neonates with severe persistent pulmonary
				hypertension refractory to high-frequency oscillatory ventilation.
        
        
          Methods:
          The birth weight and the gestational age of infants
				were 3125.5 ± 794 g (mean ± SD) and 39 ± 2.4 weeks, respectively. All
				neonates were ventilated for an average of 137.5 min (range 90-180 min) prior to
				NO therapy. The mean oxygenation index (OI) of all neonates prior to NO was
				46.3 ± 5 (mean ± SEM). NO was initially administered at 20 parts per
				million (ppm) for at least 2 h and increased gradually by 2 ppm to a maximum of
				80 ppm.
        
        
          Results:
          Eighteen infants (75%) responded and six (25%) did not respond to
				the treatment. Three neonates died in the responding group, while all the
				non-responders died (P = 0.0001). The survival rate was 62.5% among all
				neonates. NO significantly decreased OI (P < 0.0001) and improved
				the arterial/alveolar (a/A) oxygen ratio (P < 0.0001) within the
				first 2 h of NO therapy in 61.1% of the responders. However, the OI and the a/A
				oxygen ratio remained almost the same throughout the treatment in the
				non-responders and the non-survivors.
        
        
          Conclusion:
          Inhaled NO at 20 ppm, following adequate ventilation for 2 h without
				significant response, could be used to identify the majority of the
				non-responders in order to seek other alternatives.
Compound 530608: 3-Cyclopentylpropionic acid, but-3-yn-2-yl ester

Chemical compound data from PubChem database. IUPAC Name: but-3-yn-2-yl 3-cyclopentylpropanoate. Molecular Formula: C12H18O2. Molecular Weight: 194.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Changes to Medicaid eligibility for youth/young adults age 18 who transition out of foster care and move to a new state

This Information Memorandum (IM) provides child welfare agencies with information about changes in Medicaid eligibility for young adults who turn age 18 on or after January 1, 2023 who move to a new state after transitioning from foster care.

Metadata-only record linking to the original dataset. Open original dataset below.
Table 7. 2011-2012 NSDUH Cocaine Use in the Past Year, by Age Group and State

Table 7. Cocaine Use in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2011 and 2012 NSDUHs. Results are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Patent AT-E400576-T1: [Translated] 5-ALKOXYALKYL-6-ALKYL-7-AMINO-AZOLOPYRIMIDINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING HARMFUL FUNGALS AND AGENTS CONTAINING SAME

Chemical patent from PubChem database. Patent Number: AT-E400576-T1. Title: Method for Synthesizing Organic Compounds. Filing Date: 1992-07-12. Inventors: Wilson, James, Brown, Patricia, Lee, David. Abstract: A method for synthesizing organic compounds is disclosed, comprising reacting starting materials under specific conditions to yield the desired produc... IPC Classifications: C07D, A61K, A61P. This patent covers 14 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Patent AT-E401191-T1: [Translated] METHOD AND APPARATUS FOR APPLYING A REINFORCEMENT TO A PLASTIC PIPE BY A WINDOW WELDING METHOD

The invention relates to a plastic pipe (1) comprising at least one connecting point (2) for connection to another plastic pipe (3) or to another connecting piece, wherein the connecting point (2) has a sealing area. A reinforcement (5) is applied to the connecting point (2) in the sealing area and substantially or completely prevents the plastic of the connecting point (2) from creeping in the sealing area. The invention also relates to a method and devices for producing a corresponding plastic pipe.
Neglect and Prevention Policies (NAPP) Data

Neglect is a common form of child maltreatment and is a frequently occurring reason for family separation to foster care. The Neglect and Prevention Policies Data aggregates policy information using data pulled from several sources such as federal agency legislation, implementation websites, and state-level neglect statutes. Presented as several linked data tables, this data package is designed to assist child welfare researchers with analyzing how states address neglect.

Investigators: Tola Seng, MSW, 
University at Albany, State University of New York, New York

Holly White-Wolfe, PhD

Katharine Briar-Lawson, PhD, 
University at Albany, State University of New York, New York

Kristcha De Guerre, PhD, 
Galen University
2017-2018 NSDUH: P-Value Tables For Geographic Comparison

Compare state-level estimates from the 2017-2018 National Surveys on Drug Use and Health (NSDUH) using p-values. The tables accompany the2017-2018 NSDUH State Estimates of Substance Use and Mental Disorders, and can be used to determine whether the difference in estimates between two geographic areas are statistically significant. A guide to their use is also included.The tables are available in an Excel spreadsheet or a zip file containing CSV text files. Each tab or text file contains p-values for a particular measure and a particular age group.
Compound 526671: Cholan-24-oic acid, 3,7,12-tris[(trimethylsilyl)oxy]-, methyl ester, (3alpha,5beta,7alpha,12alpha)-

Chemical compound data from PubChem database. IUPAC Name: methyl 4-[10,13-dimethyl-3,7,12-tris(trimethylsilyloxy)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate. Molecular Formula: C34H66O5Si3. Molecular Weight: 639.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400819-T1: [Translated] CONTROLLED RELEASE PREPARATIONS

A solid dosage formulation having a core with a pharmacological agent dispersed in a first controlled-release matrix from which release of the agent is relatively slow; and a coat formed over the core and having the agent dispersed in a second controlled-release matrix from which release of the agent is relatively fast. The first matrix can be a cross-linked high amylose starch and the second matrix can be a mixture of polyvinyl acetate and polyvinylpyrrolidone.
Compound 526384: 1,3-Dibromo,6,8-dichloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,3-dibromo-6,8-dichlorodibenzo-p-dioxin. Molecular Formula: C12H4Br2Cl2O2. Molecular Weight: 410.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - Table II. Salmonellosis to Shigellosis

NNDSS - Table II. Salmonellosis to Shigellosis - 2017.  In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories.

Note:
These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. 

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. 

Footnotes:
 C.N.M.I.: Commonwealth of Northern Mariana Islands. 

 U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. 

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

$ Includes E. coli O157:H7, Shiga toxin-positive, serogroup non-O157, and Shiga toxin-positive, not serogrouped.
Human cytomegalovirus IE1 promoter/enhancer drives variable gene expression in all fiber types in transgenic mouse skeletal muscle

Background
          Versatile transgenic manipulation of skeletal muscle requires knowledge of the expression profiles of diverse promoter/enhancer elements in the transcriptionally specialized fiber types of which muscle is composed. "Universal" viral promoters/enhancers, e.g., cytomegalovirus IE1 (CMV IE1), are of interest as reagents that may drive broad expression. However, a previous study noted a marked heterogeneity of CMV IE1-driven transgene expression among muscle fibers, raising the possibility of fiber-type-restricted expression. The purpose of the present study was to characterize CMV IE1-driven expression in terms of fiber type.
        
        
          Results
          We produced two lines of transgenic mice carrying the CMV IE1/ β-galactosidase construct CMVLacZ, and analyzed transgene expression and fiber type by histochemical analysis of hindlimb muscle sections. In both lines CMVLacZ was expressed in all four major fiber types: type I (slow) and types IIA, IIB and IIX (fast). There was no unique pattern of fiber-type-preferential expression; fiber-type quantitative differences were observed but details varied between muscle regions and between lines. Both lines showed similar fiber-type-independent regional differences in overall expression levels, and a high level of within-fiber-type variability of expression, even among nearby fibers. The soleus muscle showed strong expression and comparatively little within-fiber-type or between-fiber-type variability.
        
        
          Conclusions
          The CMV IE1 promoter/enhancer is not fiber-type-restricted and can be useful for driving germ-line transgene expression in all four fiber types. However, not all fibers express the gene at high levels due in part to regional differences in overall expression levels, and to a high level of within-fiber-type variability. Given the multinucleate syncitial nature of muscle fibers, it is not likely that this variability is due to variegating heterochromatinization. The soleus muscle would make a suitable subject for near-uniform experimental gene expression driven by CMV IE1 elements.
Compound 529489: Propanoic acid, 3-[N-(2-formyl-5-methyl-1-pyrrolyl)]

Chemical compound data from PubChem database. IUPAC Name: 3-(2-formyl-5-methylpyrrol-1-yl)propanoic acid. Molecular Formula: C9H11NO3. Molecular Weight: 181.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527395: Heptanoic acid, 2,2-dimethyl-, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2,2-dimethylheptanoate. Molecular Formula: C10H20O2. Molecular Weight: 172.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530427: 1,4-Methanoindan, hexahydro-7-isopropyl-4-methyl-8-methylene-

Chemical compound data from PubChem database. IUPAC Name: 6-methyl-7-methylidene-3-propan-2-yltricyclo[4.4.0.02,8]decane. Molecular Formula: C15H24. Molecular Weight: 204.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527087: alpha-Phellandrene epoxide

Chemical compound data from PubChem database. IUPAC Name: 1-methyl-4-propan-2-yl-7-oxabicyclo[4.1.0]hept-2-ene. Molecular Formula: C10H16O. Molecular Weight: 152.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401303-T1: [Translated] METHOD FOR PRODUCING ED-71

Vitamin D derivatives having general formula (1) which are hydroxylated at the 24-position and considered as one of metabolites of physiologically active vitamin D derivatives substituted at the 2 beta -position wherein R1, R2, R3 and R4 are the same or different and each represents hydrogen or a protective group; X and Y represent each H or OR5, provided that Y is OR5 when X is H, and Y is H when X is OR5 (wherein R5 represents hydrogen or a protective group, or R1 and R5 may together form a vicinal-diol protective group); synthesis intermediates useful in synthesizing these vitamin D derivatives; and medicinal compositions containing these vitamin D derivatives. <CHEM>
Publications Using SAMHSA DataPortland-Vancouver-Hillsboro, OR-WA

This report presents combined 2005 to 2010 National Survey on Drug Use and Health (NSDUH) results for those aged 12 or older in the Portland-Vancouver-Hillsboro, OR-WA metro area. The report includes estimates of substance use disorder, major depressive episode, illicit drug use, marijuana use, cigarette use, binge alcohol use, and the nonmedical use of prescription-type pain relievers. Results are provided for the Pitts Portland-Vancouver-Hillsboro metro area, Oregon, and the U.S. overall.
Compound 525860: N,N-Dimethyl-2-phenyl-N'-butyl-acetamidine

Chemical compound data from PubChem database. IUPAC Name: N'-butyl-N,N-dimethyl-2-phenylethanimidamide. Molecular Formula: C14H22N2. Molecular Weight: 218.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Weekly Cumulative Estimated Number of Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States (ARCHIVED)

Weekly Cumulative Estimated Number of Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States

- Since 2019, CDC has been exploring use of data obtained from (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices. These data are being presented publicly for the first time this season; further evaluations of these data are underway.

- The pharmacy data include flu vaccinations that were billed for (i.e. claims) or paid by cash. Medical office data are claims based.

- The sampled pharmacies and physician medical offices and the captured volume of transactions represent approximately 92% and 82% of influenza vaccines administered nationally, respectively.

- Vaccinations administered in other settings such as workplaces and community settings are not included in these data.

- Weekly Number of Influenza Vaccinations Administered, in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States, Data Source(s): IQVIA Pharmacy and Physician Medical Office Claims.
Alaska (AK)

This report presents Alaska\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Alaska for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Gender-related plasma levels of progesterone, interleukin-8 and interleukin-10 during and after cardiopulmonary bypass in infants and children

Background
          It is known that proinflammatory and anti-inflammatory cytokines are released during and after cardiopulmonary bypass (CPB) in infants and children. Sex steroids are known to have immunomodulatory functions, and release of the anti-inflammatory cytokine IL-10 is stimulated by progesterone in vitro. The purpose of the present study was to investigate the plasma levels of progesterone, IL-8 (proinflammatory cytokine) and IL-10, and to relate them to sex and postoperative morbidity.
        
        
          Method
          Eighteen infants and children (eight female) undergoing CPB were prospectively studied. Plasma levels of progesterone, IL-8 and IL-10 were determined before and 10 min after the start of CPB, and immediately after CPB; and 6 h, 24 h, 3 days and 7 days postoperatively. Organ dysfunction was identified on the basis of arbitrarily defined criteria.
        
        
          Results
          After CPB, all patients showed significant increases in plasma levels of progesterone, IL-8 and IL-10. Plasma levels of IL-10 were significantly higher in female patients, except for during the immediate postoperative period. According to the criteria used, six out of 10 male patients, but none of the female patients developed multiple organ dysfunction (MOD).
        
        
          Conclusion
          The present study shows that CPB induces a significant and marked increase in plasma levels of progesterone in infants and children. Studies of administration of progesterone-blocking substances to male and female animals may help to elucidate the roles of sex and progesterone in the setting of CBP.
Physicians' preference values for hepatitis C health states and antiviral therapy: A survey

Background
          Physicians' perspectives regarding hepatitis C shape their approach to patient management. We used utility analysis to evaluate physicians' perceptions of hepatitis C-related health states (HS) and their threshold to recommend treatment.
        
        
          Methods
          A written questionnaire was administered to practicing physicians. They were asked to rate hepatitis C health states on a visual analog scale ranging from 0% (death) to 100% (health without hepatitis C). Physicians then judged quality of life associated with the side effects of antiviral therapy for hepatitis C and indicated the sustained virological response rate that they would require to recommend treatment.
        
        
          Results
          One hundred and thirteen physicians from five states were included. Median utility ratings for hepatitis C health states declined significantly with increasing severity of symptoms: HS1-No Symptoms, No Cirrhosis (88%; 12% reduction from good health), HS2-Mild Symptoms, No Cirrhosis (66%), HS3-Moderate Symptoms, No Cirrhosis (49%), HS4-Mild Symptoms, Cirrhosis (40%), HS5-Severe Symptoms, Cirrhosis (18%) [p < 0.001]. The median rating for life with side effects of antiviral therapy was 47%, suggesting a 53% reduction from good health. That was similar to the utility value for HS3-Moderate Symptoms, No Cirrhosis. The median threshold value for recommending treatment was a sustained response rate of 60%.
        
        
          Conclusions
          1) Physicians' utility ratings for hepatitis C health states were inversely related to the severity of disease manifestations described. 2) Physicians viewed side effects of therapy unfavorably and indicated that on average, they would require a 60% sustained response rate before recommending treatment, which far exceeds the efficacy of current antiviral therapy for hepatitis C in the majority of patients.